Sample Alerts - inThought Research

Poseida finally pulls plug on autologous BCMA CAR-T program

HIGH IMPACT - Poseida announced in its Q3 press release that it will end its P-BCMA-101 autologous CAR-T program and prioritize its allogeneic CAR-T P-BCMA-ALLO1. “While we believe the P-BCMA-101 autologous program has competitive advantages…

Analysis

Reata Submits NDA for Bardoxolone in Alport Syndrome

HIGH IMPACT - Reata has submitted an NDA to the FDA for bardoxolone methyl for the treatment of chronic kidney disease caused by Alport Syndrome. Reata has requested priority review for the application. The submission was based on the results…

Analysis

Prothena Reports Q4 2020 & Full Year Earnings

HIGH IMPACT - During its Q4 2020 earnings call, Prothena gave an update on its prasinezumab clinical program for Parkinson’s disease. During the clinical overview, Prothena highlighted that prasinezumab specifically targets the C-terminus…

Analysis

BCMA Bispecific Earnings Roundup: Pfizer’s Elranatamab Granted FDA Fast Track Designation While Amgen’s Pavurutamab Trial is Paused Due to Safety

HIGH IMPACT - Both Pfizer and Amgen provided updates on its BCMA bispecific programs in Q4/FY 2020 earnings calls on February 2. Pfizer’s BCMAxCD3 bispecific, elranatamab (PF-06863135), received FDA Fast Track designation in late January…

Analysis

TOXINS 2021: Ipsen to Present New Analysis of Phase 3 Data Demonstrating the long-duration of Dysport in Five Therapeutic Indications

MODERATE IMPACT Ipsen will present 26 abstracts at TOXINS 2021. A key presentation titled AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations demonstrates long-duration of Dysport. Data from the…

Analysis

Affimed’s AFM13 in Combination with Keytruda Demonstrates Promising Early Stage Results for Patients with r/r Hodgkin Lymphoma

November 19, 2020 Impact: High Results for Affimed’s AFM13 (CD30/CD16A ICE; Innate Cell Engager) in combination with Keytruda (pembrolizumab) in a phase 1b study for r/r Hodgkin Lymphoma patients have been published in the journal…

Contact Us